Study of Beta-cell Response to Incretin Hormones GLP-1 and GIP in Adults with Cystic Fibrosis and Pancreatic Insufficiency

What this Trial Is About

Researchers are studying the complex relationship between cystic fibrosis CF and a form of diabetes known as cystic fibrosis related diabetes CFRD. This condition has features similar to both type 1 and type 2 diabetes, but CF patients may exhibit different symptoms. The study aims to better understand the mechanisms behind CFRD and explore how incretin hormones, which stimulate insulin production, may affect insulin release in CF patients. Participants will receive infusions of two incretin hormones, GLP-1 and GIP, during glucose pancreatic assessment GPA tests. The incretin infusion starts 30 minutes before the GPA test and continues for 90 minutes during the test at a glucose level of 230 mgdL, then stops as the test continues at 340 mgdL without incretin. Each participant will also undergo the same GPA test with a placebo infusion for comparison. The study includes CF patients with normal glucose tolerance and non-CF control participants. During the study, participants undergo GPA tests to measure the second-phase insulin response, which reflects how beta cells in the pancreas release insulin. The research team will monitor insulin secretion changes over five hours, comparing responses during incretin and placebo infusions. The study is randomized and quadruple-blinded, ensuring unbiased results. Participants will be closely observed for safety and adherence to study procedures throughout the process.

Beta-cell Response to Incretin Hormones in Cystic Fibrosis